Abstract--Familial hypercholesterolem& (FH) is an inherited deficiency of LDL receptors that
INTRODUCTION
Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by defects in the gene encoding LDL receptor (1) . Patients who inherit two abnormal LDL receptor alleles provide an excellent model for the early development of gene replacement therapies. Homozygous FH is truly a lethal disease with patients developing lifethreatening coronary heart disease (CHD) in childhood due to massive accumulations of LDL that are refractory to traditional pharmacological therapies. Metabolic correction has been achieved in FH homozygotes by orthotopic liver transplantation, indicating that selective correction of LDL receptor expression in hepatocytes by liver-directed gene therapy should be sufficient for improvement in hypercholesterolernia (2) (3) (4) . The observation that FH homozygotes with residual LDL receptor activity have a better prognosis than those with null genotypes suggests that partial genetic correction may be therapeutic (1) . Finally, the availability of an authentic animal model for FH, the Watanabe heritable hypertipidemic (WHHL) rabbit, greatly facilitates the evaluation of new genetic therapies (5) (6) (7) .
The early paradigm for gene therapy of FH was based on transplantation of autologous hepatocytes transduced with recombilpresent address for all authors: Institute for Human Gene Therapy, Furthermore, the efficacy is necessarily limited by the number of hepatocytes that can be harvested, manipulated ex vivo, and transplanted, which has never been greater than 5% of the total cells in liver (8) . Finally, the complexity of the protocol severely restricts its application. A more practical and potentially effective approach to gene therapy of FH is direct delivery of the gene to hepatocytes in vivo. This has been accomplished in the WHHL rabbit by infusion of synthetic molecular conjugates that are tropic for hepatocytes (11) . However, the level of recombinant gene expression achieved in recipient animals was low and the effect was transient. Another potential approach to in vivo liver-directed gene therapy utilizes replication defective recombinant adenoviruses (12) . Important advantages of adenoviruses for gene transfer to the liver include: (1) virus is easily purified at high concentrations (i.e., approximately 1013 particles/ml), and (2) gene transfer can be accomplished in nondividing cells. The utility of recombinant adenoviruses for in vivo gene therapy was first demonstrated in a mousemodel of the liver metabolic disease caused by ornithine transcarbamylase deficiency (13) . A similar approach has been used to deliver recombinant reporter genes to rat liver (14) and a human LDL receptor gene to mouse liver (15) .
We describe in this report an important step toward the development of in vivo gene therapy of FH with recombinant adenoviruses. Primary cultures of hepatocytes from patients with homozygous FH were corrected without apparent toxicity by single exposure to low concentrations of recombinant virus. (18) , which contains a partial E3 deletion] that had been digested with Xbal and Clal to remove the 5' ITR. Recombinant adenoviruses were isolated following transfection (19) , subjected to two rounds of plaque purification, and lysates were purified by cesium chloride centrifugation (20) . The viral stocks were evaluated for titer by limiting dilution plaque assay on 293 cells and stored at -20°C after diluting fourtbld with 10 mM Tris CI, pH 8.1, 100 mM NaCI, 0.1% bovine serum albumin, and 50% glycerol. Titers of the glycerol stocks were: Ad.CBlacZ, 2.4 × 109 plaque-forming units (PFU)/ml; Ad.CBhLDLR, 4 x 109 PFU/ml; wild-type Ad, 8 x 109 PFU/ml.
MATERIALS AND METHODS

Recombinant
Isolation and Propagation of Hepatocytes.
Hepatocytes were isolated from liver tissue by in situ perfusion of collagenase as described (21) . Cells were plated at a density of 4 x 106 cells/10 cm 2 plate in Hormonally defined medium (HDM) supplemented with 10% FCS overnight and subsequently maintained in HDM alone.
Electron Microscopy. Plates of hepatocytes were fixed 24, 48, and 72 h after plating in 1.6% formaldehyde/2% gluteraldehyde in 0.1 M cacodylate buffer for 1 h at 4°C, then washed in 0.1 M cacodylate, and postfixed in 1.5% osmium tetroxide in 0.1 M cacodylate buffer for 30 min at 4°C. Samples were processed, stained, and analyzed by transmission electron microscopy as described (22) .
Hepatocyte Infection. NonFH and FH
hepatocytes plated in HDM (without serum) were infected with purified recombinant adenovirus [multiplicity of infection (MOI) = 0.1, 1, or 10] one to three days after plating; an estimate of cell number, based on inspection of the plate, was used to calculate the MOI. Two days following infection the ceils were analyzed for lacZ or LDL receptor expression as described below.
CytochemicalAnalyses. Plates of hepatocytes were analyzed for [3-galactosidase expression using the X-gal histochemical stain (23) and for LDL receptor activity using an in situ activity assay based on the uptake of fluorescent labeled ligand. The LDL receptor assay was performed as follows. Hepatocytes were incubated with DMEM supplemented with 10% calf lipoprotein-deficient serum and 10 Ixg/mt of LDL labeled with the fluorescent probe l,l'-dioctadecyl-3,3,3',3'-tetramethyl indocarbocyanine perchloridate (diI-LDL; gift of Bruce Auerbach, ParkeDavis, Ann Arbor, Michigan). Following a 4-h incubation, cells were rinsed with DMEM and diI-LDL uptake was visualized by fluorescent microscopy as described (16 (24) was also included. The gel was transferred to nitrocellulose and the filters probed (24) . The antibodies used were a monoclonal anti-[3-galactosidase antibody (IgG1) from Sigma, diluted 1:500, and a monoclonal anti-human LDLR antibody (IgG1) from Amersham (Arlington Heights, Illinois), diluted to I Ixg/ml. Following incubation with a peroxidase-conjugated goat anti-mouse IgG antibody diluted 1:1000, the filters were washed, then incubated with ECL (Amersham) according to the manufacturer's directions, and exposed to Kodak XAR-5 X-ray film.
RESULTS AND DISCUSSION
The design of safe and efficient methods for delivering recombinant genes to hepatocytes in vivo would greatly enhance the utility of liver-directed gene therapy. Previous attempts using liposomes (25) or DNA/ protein complexes (11, 26) resulted in levels of expression that were inadequate for therapeutic effects. Direct infusion of recombinant retroviruses into the portal vein after partial hepatectomy is associated with gene transfer in only a few percent of hepatocytes (27) . Experiments with rats and mice indicate that infusion of recombinant adenoviruses in the absence of partial hepatectomy or injury to the liver is associated with high-level transgene expression in the majority of hepatocytes (13-15, and unpublished data). In this report, we explore the feasibility of using recombinant adenoviruses to correct a genetic deficiency of LDL receptor in primary" hepatocytes of patients with FH.
Hepatocytes were isolated from liver tissue of a normal donor (Z8) and two FH patients (FH2 and FH3) . A summary of the salient features of the patients and the cell isolations is provided in Table 1 . A portion of a donor liver from a nonFH patient that was surgically reduced prior to transplantation was used as a source of normal hepatocytes. Hepatocytes from two FH patients (designated FH2 and FH3) were isolated from freshly resected liver that was used for ex vivo gene therapy; additional plates of cells not suitable for transplantation were used in these experiments. The recovery of hepatocytes from the collagenase perfusions ranged from 4.4 to 20 x 106 cells/g wet weight of tissue with a viability of 92-93%. Cells were maintained in culture for four days. Representative electron photomicrographs of cells from FH3 are presented in Fig. 1 . Greater than 95% of the cells retained ultrastructural features specific to hepatocytes for the duration of the experiment, confirming the purity of the preparation and the stability of the cultures in terms of hepatocyte differentiation. This experience with hepatocytes from FH patients is consistent with our previous studies with liver from four nonFH patients (21). Conditions required for efficient adenovirus-mediated gene transfer were established with normal hepatocytes using the Ad.CBlacZ virus. Purified virus was diluted into HDM and added directly to the cultured hepatocytes 24-72 h after plating; cells were harvested for evaluation of transgene expression 24 h later. Figure 2 presents X-gal histochemistry of normal hepatocytes that were mock infected (panel A) or infected with Ad.CBlacZ at an MOI of 0.1 (panel B) and 1.0 (panel C). The efficiency of gene transfer was directly proportional to the concentration of virus added to the medium with essentially 100% of the cells expressing high levels of lacZ when cells were exposed Fig. 2 . X-gal histochemistry of infected hepatocytes. Normal human hepatocytes were infected two days after plating with Ad.CBhLDLR at a MOI of 1 (A), or with Ad.CBlacZ at a MOI of 0.1 (B) or 1 (C), and stained one day postinfection with X-gal.
to virus at an MOI of 1 without apparent cytopathic effects. Additional experiments have demonstrated that cytopathology does not occur until the MOI is equal to or greater than 50 (data not shown).
Hepatocytes from the two FH patients were exposed to Ad.CBlacZ and Ad.CBhLDLR at MOIs equal to 1 and 10, and whole cell lysates were analyzed for [3-galactosidase and LDL receptor by Western blot analysis (Fig. 3) . Analysis with antibody to [3-galactosidase revealed a predominant band at 116 kDa that was specific to lysates from Ad.CMVlacZ-infected cells and comigrated with purified [3-galactosidase enzyme. Analysis with a monoclonal antibody to human LDL receptor revealed a 130-kDa band in lysates from liver and cultured hepatocytes of a normal donor. This was not present in cultured hepatocytes from either FH patient, indicating their mutations are associated with quantitative defects in LDL receptor expression. In contrast, extremely high quantities of LDL receptor protein were detected in lysates of FH hepato~-te s exposed to the Ad.CBhLDLR virus; the level of recombinant LDL receptor protein in ceils infected at an MOI of 10 exceeded the levels in nonFH liver or hepatocytes by at Ieast 20-fotd. Fig. 3 . Western blot analysis of infected hepatocytes, kysates were prepared from infected cells and were subjected to SDS-PAGE followed by transfer to nitrocellulose. Filters were incubated with either an anti-13-galactosidase monoclonal antibody (left panels) or with an anti-human LDL receptor monoclonat antibody (right panels). !3-gal, purified 13-galactosidase; lacZ 1 and lacZ 10, FH hepatocytes infected with Ad.CBlacZ at MOIs of ! and 10, respectively; LDLR 1 and LDLR 10, FH hepatocytes infected with Ad.CBhLDLR at MOIs of 1 and 10, respectively; Hep, normal human hepatocytes; liver, extract prepared from normal human liver. In each experiment, lanes derived from normal hepatocytes and liver were from the same blot, but exposed three times longer than lanes derived from FH hepatocytes.
FH hepatocytes were analyzed for functional LDL receptor activity using an in situ assay that is based on the receptormediated uptake of fluorescent-labeled LDL. Figure 4 presents fluorescent micrographs of FH3 hepatocytes that were infected with Ad.CBlacZ at an MOI of 10 (panels A and B) and Ad.CBhLDLR at an MOI of 1 (panels C and D) and 10 (panels E and F). No fluorescence was detected in the Ad.CMVlacZ-infected cells, with 75% of the cells demonstrating high levels of LDL uptake after exposure to Ad.CBhLDLR virus at an MOI equal to 10.
The recombinant adenoviruses used in this study were disabled by deleting Ela and Elb, which are normally required to activate the expression of other viral genes. It is possible, however, that this block in activation can be overcome by cellular factors or by exposing the cells to high MOIs of replication defective adenovirus. Experiments in human bronchial xenografts using the same viruses have demonstrated a block in transi- Fig. 4 . LDL uptake assay of infected FH hepatocytes. FH hepatocytes were infected two days after plating with Ad.CBlacZ at a MOI of 10 (A, B), or with Ad.CBhLDLR at a MOI of 1 (C, D) or 10 (E, F). Twenty-four hours after infection, cells were incubated with medium containing 10% calf lipoprotein-deficient serum and 10 ~g/ml diI-LDL for 4 h. Panels A, C, and E are phase-contrast pictures, and panels B, D, and F are the corresponding fields viewed using fluorescence optics.
tion from early to late transcriptional units with high level expression of the early gone E2a (20) . Similar techniques of immunocytochemistry were used to study the expression of adenoviral proteins in human hepatocytes exposed to adenoviruses. Expression of the early gone E2a and the late gone L5 was evaluated using antibodies to the corresponding gene products, the 72-kDa DNA binding protein and the fiber protein, respectively (Fig. 5) . In each case, cells were harvested for analysis 16-18 h after exposure to virus.
The 293 cells exposed to Ad.CMVlacZ (which replicates due to 293 cells providing the E1 gone products in trans) demonstrated DBP and fiber protein in virtually all cells (Fig. 5A-C) ; panel B shows punctate nuclear staining characteristic of DBP and panel C shows dark cytoplasmic staining characteristic of fiber. Human hepatocytes infected with wild-type Ad5 demonstrated high levels of DBP and trace levels of fiber in subpopulations of cells (Fig. 5D-F) ; no viral proteins were detected in human hepatocytes infected with the recombinant virus (Fig. 5G-I) .
In summary, we show that recombinant adenoviruses based on human Ad5 are capable of very efficiently transducing genes into human hepatocytes without apparent cytopathic effects or expression of adenoviral proteins. This approach was used to fully correct the genetic defect in hepatocytes isolated from patients with FH. The encouraging results in human hepatocytes along with previous studies in rodents suggest that recombinant adenoviruses may be useful in the development of in vivo liver-directed gene therapies in humans. However, several important issues remain regarding the utility of recombinant adenoviruses for gene therapy of FH. The effects of high-level constitutive expression of LDL receptor and its ability to catabolize LDL have to be addressed. In addition, it will be necessary to develop strategies for,achieving prolonged transgene expression in vivo.
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